CN116785209A - Application of agilawood hydrolat and skin external preparation containing agilawood hydrolat - Google Patents
Application of agilawood hydrolat and skin external preparation containing agilawood hydrolat Download PDFInfo
- Publication number
- CN116785209A CN116785209A CN202210264828.2A CN202210264828A CN116785209A CN 116785209 A CN116785209 A CN 116785209A CN 202210264828 A CN202210264828 A CN 202210264828A CN 116785209 A CN116785209 A CN 116785209A
- Authority
- CN
- China
- Prior art keywords
- agilawood
- skin
- hydrolat
- care products
- skin care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 23
- 230000000694 effects Effects 0.000 claims abstract description 56
- 241000271309 Aquilaria crassna Species 0.000 claims abstract description 51
- 230000006870 function Effects 0.000 claims abstract description 22
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 101800005049 Beta-endorphin Proteins 0.000 claims abstract description 13
- 102100027467 Pro-opiomelanocortin Human genes 0.000 claims abstract description 13
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 claims abstract description 13
- 108010025083 TRPV1 receptor Proteins 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 230000008439 repair process Effects 0.000 claims abstract description 8
- 206010051246 Photodermatosis Diseases 0.000 claims abstract description 7
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 7
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 7
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 7
- 230000004064 dysfunction Effects 0.000 claims abstract description 7
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 7
- 210000005036 nerve Anatomy 0.000 claims abstract description 7
- 230000001953 sensory effect Effects 0.000 claims abstract description 7
- 230000006378 damage Effects 0.000 claims abstract description 6
- 230000008845 photoaging Effects 0.000 claims abstract description 6
- 210000003491 skin Anatomy 0.000 claims description 81
- 210000002510 keratinocyte Anatomy 0.000 claims description 71
- 210000004027 cell Anatomy 0.000 claims description 60
- 210000002950 fibroblast Anatomy 0.000 claims description 31
- FBEHFRAORPEGFH-UHFFFAOYSA-N Allyxycarb Chemical compound CNC(=O)OC1=CC(C)=C(N(CC=C)CC=C)C(C)=C1 FBEHFRAORPEGFH-UHFFFAOYSA-N 0.000 claims description 28
- 230000001737 promoting effect Effects 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 11
- 229920002674 hyaluronan Polymers 0.000 claims description 11
- 229960003160 hyaluronic acid Drugs 0.000 claims description 11
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 102000010637 Aquaporins Human genes 0.000 claims description 8
- 108010063290 Aquaporins Proteins 0.000 claims description 8
- 102000012422 Collagen Type I Human genes 0.000 claims description 8
- 108010022452 Collagen Type I Proteins 0.000 claims description 8
- 101710197056 Hyaluronan synthase 2 Proteins 0.000 claims description 8
- 102100040206 Hyaluronan synthase 2 Human genes 0.000 claims description 8
- 230000008591 skin barrier function Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 102000000591 Tight Junction Proteins Human genes 0.000 claims description 5
- 108010002321 Tight Junction Proteins Proteins 0.000 claims description 5
- 210000003470 mitochondria Anatomy 0.000 claims description 5
- 102000011154 Tight junction protein ZO-1 Human genes 0.000 claims description 4
- 108050001370 Tight junction protein ZO-1 Proteins 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 210000001578 tight junction Anatomy 0.000 claims description 3
- 102000002464 Galactosidases Human genes 0.000 claims description 2
- 108010093031 Galactosidases Proteins 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 238000005728 strengthening Methods 0.000 claims description 2
- 230000035882 stress Effects 0.000 abstract description 13
- 230000004663 cell proliferation Effects 0.000 abstract description 5
- 230000005808 skin problem Effects 0.000 abstract description 5
- 230000000202 analgesic effect Effects 0.000 abstract description 4
- 239000000419 plant extract Substances 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000009759 skin aging Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 36
- 241001533085 Aquilaria sinensis Species 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 239000003755 preservative agent Substances 0.000 description 18
- 230000002335 preservative effect Effects 0.000 description 18
- 102000004889 Interleukin-6 Human genes 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 239000000341 volatile oil Substances 0.000 description 15
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 14
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 14
- 241000609666 Tuber aestivum Species 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 12
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical group CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- -1 religions Substances 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
- 239000003205 fragrance Substances 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000000770 proinflammatory effect Effects 0.000 description 10
- 239000003642 reactive oxygen metabolite Substances 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 9
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 229940101267 panthenol Drugs 0.000 description 9
- 235000020957 pantothenol Nutrition 0.000 description 9
- 239000011619 pantothenol Substances 0.000 description 9
- 150000005846 sugar alcohols Polymers 0.000 description 9
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 210000003837 chick embryo Anatomy 0.000 description 8
- 230000009194 climbing Effects 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 239000000834 fixative Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229940049964 oleate Drugs 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- 229960003415 propylparaben Drugs 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000000230 xanthan gum Substances 0.000 description 8
- 229920001285 xanthan gum Polymers 0.000 description 8
- 229940082509 xanthan gum Drugs 0.000 description 8
- 235000010493 xanthan gum Nutrition 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 229960002504 capsaicin Drugs 0.000 description 6
- 235000017663 capsaicin Nutrition 0.000 description 6
- 239000012930 cell culture fluid Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 5
- 102100028314 Filaggrin Human genes 0.000 description 5
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 5
- 102000003940 Occludin Human genes 0.000 description 5
- 108090000304 Occludin Proteins 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 235000013599 spices Nutrition 0.000 description 5
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 4
- 239000004925 Acrylic resin Substances 0.000 description 4
- 229920000178 Acrylic resin Polymers 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- 108010022355 Fibroins Proteins 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 4
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 4
- 229940093629 isopropyl isostearate Drugs 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 108090000312 Calcium Channels Proteins 0.000 description 3
- 102000003922 Calcium Channels Human genes 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010049140 Endorphins Proteins 0.000 description 3
- 102000009025 Endorphins Human genes 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 208000024248 Vascular System injury Diseases 0.000 description 3
- 208000012339 Vascular injury Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 241000589634 Xanthomonas Species 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 description 3
- 150000004777 chromones Chemical class 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000003938 response to stress Effects 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 229930004725 sesquiterpene Natural products 0.000 description 3
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 2
- 229940035437 1,3-propanediol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 241000984061 Aquilaria Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102100025255 Haptoglobin Human genes 0.000 description 2
- 208000031361 Hiccup Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 102000003563 TRPV Human genes 0.000 description 2
- 108060008564 TRPV Proteins 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 210000001643 allantois Anatomy 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000013100 final test Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical group O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010181 skin prick test Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 108010027843 zonulin Proteins 0.000 description 2
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 102100039285 Hyaluronidase-2 Human genes 0.000 description 1
- 101710199674 Hyaluronidase-2 Proteins 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 231100001224 moderate toxicity Toxicity 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to the field of daily necessities and plant extracts, and discloses application of agilawood hydrolat. The agilawood hydrosol can be used for preparing skin care products with the following functions: anti-aging, antioxidant, moisturizing, improving skin stress, inhibiting photoaging damage or repairing skin. The Chinese eaglewood hydrolat has high activity and good safety, can promote cell proliferation and expression of protein related to moisture preservation, improve the repair capability of skin, stabilize the structure and function of the skin, and delay skin aging; regulating the expression of TRPV1 receptor, improving the cutaneous sensory nerve dysfunction; promote the release of natural analgesic factor beta-endorphin, relieve the skin problem caused by pressure, thus having good application prospect.
Description
Technical Field
The invention relates to the field of daily necessities and plant extracts, in particular to application of agilawood hydrolat and an external skin preparation containing the agilawood hydrolat.
Background
Agalloch eaglewood is a resin-containing core formed by trees of the genus Aquilaria (Aquilaria lam.) which belongs to the family daphnaceae in terms of taxonomy, and so far, it has been well recognized that there are 19 varieties of agalloch eaglewood which can produce fragrance, and the agalloch eaglewood produced in China is mainly produced in the islands of Hainan, taiwan, guangdong and Guangxi. Agilawood has a long history of use in medicine, daily chemicals, religions, and fragrance cultures. Agilawood serves as perfume and is the first of four major perfumes of 'Zhuan Sanlong musk'. The earliest recorded in Ming Yi Bie Lu (miscellaneous records of famous physicians) of Liang Daitao is listed as the top grade. The "Ben Cao gang mu" describes agilawood: for upper heat and lower cold, dyspnea and urgent asthma, deficiency and closed large intestine, heart-mind deficiency, and long-term hiccup due to stomach cold. Original materia medica record: "Chen Xiang tonify kidney, vital gate, invigorate spleen and stomach, benefit Qi and harmonize spirit". The "sea medicine herbal" describes the following agilawood: mainly heart abdominal pain, cholera, aversion to evil, clear people's mind. The Chinese pharmacopoeia records that the agilawood has the effects of promoting qi circulation, relieving pain, warming middle energizer, relieving vomiting and relieving asthma. Agilawood is one of the traditional rare Chinese medicinal materials and ten broad-spectrum medicines in China. It has pungent, bitter and slightly warm nature, and has the actions of promoting qi circulation, relieving pain, warming middle energizer, arresting vomiting, and relieving asthma, and can be used for treating chest and abdomen distention, pain, vomiting and hiccup due to stomach cold, and dyspnea due to adverse flow of qi due to kidney deficiency. The Chinese eaglewood medicinal materials are domestic eaglewood and imported eaglewood, which are produced in China, japan, india and other eastern Asia countries, and the domestic eaglewood is aquilaria sinensis of the eaglewood genus of the daphnaceae family and woods containing resin of the plants of the same genus, and are mainly produced in areas such as Hainan, guangdong, guangxi, yunnan, taiwan and the like.
The agilawood is mainly used for preparing perfume products, perfumes, important formulas and other products. The agilawood has the pharmacological effects of resisting bacteria, calming, relieving spasm, easing pain, relieving asthma, reducing blood pressure and the like, and the incense product prepared by the agilawood has the effects of inhibiting bacteria, refreshing air, refreshing, and the like, can prevent epidemic diseases, and even has good relieving and treating effects on respiratory diseases, heart diseases, angina and the like; meanwhile, the fragrance of the agilawood can enable people to feel comfortable, the channels are smooth, and the qi movement is harmonized, so that the agilawood has very important application value in daily use and medicinal aspects.
The heavy essential oil is low-polarity oily substance with fragrance extracted from agilawood, is essence obtained by extracting and concentrating original aroma components in agilawood, is not a substance with single component, but a mixture composed of various chemical substances, and mainly comprises sesquiterpenes, aromatic substances, chromones, fatty acids and other substances. The heavy essential oil is often used as natural plant essential oil, has unique fragrance and flavor, is generally divided into front fragrance, middle fragrance and tail fragrance, has rich and changeable fragrance and is rich in bottom notes, and meanwhile, the heavy essential oil has certain efficacy on the central nervous system, the digestive system, the respiratory system and the circulatory system of a human body. The agilawood essential oil extraction method has various types, including a water distillation extraction method, a solvent extraction method, a supercritical extraction method, a subcritical extraction method and the like, and a large amount of pure dew can be produced in the process of extracting the essential oil by water vapor.
The pure dew is a byproduct of extracting essential oil, generally a saturated distillation stock solution which is separated in the process of distilling and extracting the essential oil, contains water-soluble substances and a small amount of essential oil components in all plants, is easily absorbed by skin, and is mild and not irritated. However, at present, few reports about the actual efficacy of the agilawood hydrolat on cosmetics are provided, the research is not deep enough, and the mechanism and the efficacy of the agilawood hydrolat are not much verifiable. Agilawood hydrolat has been reported as an antioxidant or free radical scavenging ingredient.
The life now faces various pressures on all sides, and long-term pressures can have negative effects on human health in many ways. Both short-term and long-term stress can trigger various chemical and hormonal responses in the body. When a person feels stress, the body reacts in a variety of ways. These auto-reactions can lead to inflammation and increase skin reactivity and sensitivity.
Stress can also exacerbate autoimmune diseases and inflammation, such as eczema, psoriasis, and rosacea. Even a small amount of anxiety can cause excessive stress on the body, leading to burning or itching of the skin.
Moreover, when a person experiences stress, the repair mechanism of the skin is also impaired. In one study, scientists at the university of kannel, wil, medical college (Weill Medical College of Cornell University) cut small wounds in the skin of volunteers with tape, and then place the volunteers in a stressful environment: false job interviews. In this pressure-sensing situation, their skin heals longer than usual. Cornell university dermatology principle Charles doctor: "in this study, even with relatively slight pressure, subjects know that the interview is false, affecting your skin function. "
The fragile muscle due to stress and the like requires extra attention and care, and more studies have found that the cutaneous nervous system also plays a role in skin sensitivity. Two specific TRPV genotypes were found to be associated with skin sensitivity, with TRPV1 being a non-selective cation channel associated with neurogenic inflammation and the itch line, possibly related to the occurrence mechanism of skin sensitivity. TRPV1 receptors are proteins located on the cell membrane and consist of four subunits, each with 6 transmembrane helices and cytoplasmic N-and C-termini. The receptor plays an important role in pain generation and transmission, and activation of the receptor can produce burning pain.
Beta-endorphin is a hormone secreted by brain in human body, is an endogenous peptide substance with morphine function produced in vivo, is a natural analgesic for human body, and is a pleasurable effect of endorphin. Dopamine (pleasurable hormone) is released when endorphins bind to receptors of the central nervous system. Endorphins can fight pain, excite spirit, alleviate depression, enter dream smoothly, regulate emotion, improve immunity, and can help to get achievement sense and calm the heart.
Skin immunity is impaired, and is more susceptible to external stimuli such as sun (UV) damage, air pollution, climate change, etc. The damaged skin barrier is more required to timely moisturize and relieve the problems of skin dryness, skin inflammation and the like. Whereas the problematic skin caused by external irritation and internal stress requires more mild, safe and effective ingredients and products to repair and resist external irritation.
Accordingly, there is a need to provide a new skin care composition to address the above skin problems.
Disclosure of Invention
The invention aims to disclose application of agilawood hydrolat and skin external preparation containing agilawood hydrolat.
The invention discloses agilawood hydrolat, effects and application thereof, and skin external preparation containing the agilawood hydrolat.
The agalloch eaglewood hydrosol is resin-containing heart agalloch eaglewood formed by trees of the genus agalloch eaglewood (Aquiaria lam.), and condensate distilled in the process of extracting essential oil has natural and pure components and light and unique fragrance. The active components of the plant essential oil comprise trace essential oil components and various water-soluble substances in plants, and mainly comprise sesquiterpenes, aromatic substances, chromones, fatty acids and the like.
The agilawood hydrolat can be prepared by a distillation method, and is saturated agilawood hydrolat.
A preferred method is that the agalloch eaglewood is prepared by steam distillation, water is added into agalloch eaglewood powder which is taken as a raw material, distillation is carried out for 4-10 hours at the temperature of 90-100 ℃, and saturated water solution of agalloch eaglewood of the lower layer of essential oil is collected, namely saturated agalloch eaglewood hydrol is obtained.
Preferably, the dosage ratio of the agilawood powder to the water is 1kg:10-40L, preferably 1kg:15-30L. The agalloch eaglewood powder is sieved by a No. 4 sieve (65 meshes).
The agilawood hydrosol is used as an active ingredient, can repair fragile muscles caused by exogenous stimulation and endogenous pressure, can target and regulate the expression of a TRPV1 receptor, and can improve cutaneous sensory nerve dysfunction; promoting secretion of beta-endorphin, positively affecting skin problems caused by stress, and helping to maintain skin stable and comfortable.
Also has antiaging effect, and can inhibit beta-galactosidase content, which is one of aging indexes induced by UV.
The ultraviolet light can also be used for resisting photoaging and repairing active ingredients, effectively eliminating ROS and superoxide generated by UV induction, resisting oxidative stress, protecting the mitochondrial function of cells and maintaining the skin healthy and stable; can promote fibroblast proliferation and type I collagen synthesis, improve muscle sole, and play a role in repairing.
Can also effectively improve various stress reactions of skin, and maintain skin balance by inhibiting the release of pro-inflammatory factor TNF-alpha or inflammatory factor IL-6, and thus can be used as skin barrier conditioning component in skin external preparation.
The Chinese eaglewood hydrol can effectively improve various stress reactions of skin, and maintain skin balance by inhibiting the content of pro-inflammatory factor TNF-alpha and the content of inflammatory factor IL-6, so that the Chinese eaglewood hydrol can be used as a skin barrier conditioning component in skin external preparations.
The eaglewood hydrol can also improve the content of the epidermal cell filaggrin FLG, the content of the zonulin ZO-1 and the content of the Occludin, so that the eaglewood hydrol can be used as a skin barrier conditioning component in a skin external preparation.
The agilawood hydrolat can also promote the content of epidermis hyaluronic acid and the content of hyaluronic acid synthase 2 and improve the expression of moisture-retention related aquaporin AQP3, so the agilawood hydrolat can be used as a moisture retention component of skin external preparations.
In summary, the agilawood hydrolat can be used for preparing skin care products, and the skin care products have at least one of the following functions: anti-aging, antioxidant, moisturizing, improving skin stress, inhibiting photoaging damage or repairing skin.
Further, the skin care product has at least one of the following functions: promoting proliferation of keratinocyte or fibroblast, stabilizing skin structure and function, strengthening skin barrier, improving skin sensory nerve dysfunction, relieving skin pain, relieving skin inflammation, and improving oxidation resistance of mitochondria.
The skin care product has at least one of the following functions: promoting ATP energization of keratinocytes and fibroblasts, promoting keratinocyte repair and migration, promoting synthesis of hyaluronic acid by keratinocytes, increasing content of hyaluronic acid synthase 2 in keratinocytes, and promoting synthesis of aquaporin by keratinocytes.
The skin care product has at least one of the following functions: the content of the keratinocyte tight junction protein ZO-1 is improved, the tight junction among cells is enhanced, and the content of the keratinocyte closure protein is improved.
The skin care product has at least one of the following functions: inhibit galactosidase activity or promote the production of type I collagen by fibroblasts.
The skin care product has at least one of the following functions: inhibiting UV-induced ROS, inhibiting UV-induced superoxide or reducing superoxide levels within the mitochondria of fibroblasts.
The skin care product has at least one of the following functions: promote the secretion of beta-endorphin by fibroblasts, inhibit the production of inflammatory factors or inhibit the production of TRPV1 receptor proteins. The inflammatory factor is TNF-alpha or IL-6.
The agilawood hydrolat disclosed by the invention is good in safety, has no influence on membrane permeability and integrity of epithelial cells, can promote cell proliferation and increase cell ATP energy, and has a good repairing effect; through chick embryo experiments, the agalloch eaglewood hydrol has no potential irritation; the repeated skin prick and skin allergy test researches show that the agilawood hydrolat has low irritation, safety and reliability.
The agilawood hydrolat in the skin external agent applied as the efficacy is 0.001-100 wt%.
The external skin preparation refers to a product which is spread on any part of the surface of the human body by painting, spraying or other similar methods to achieve cleaning, maintenance, beauty, modification and change of appearance, or to correct the smell of the human body and maintain a good state. The skin external agent may be a basic cosmetic, a facial cosmetic, a head care product, a body care product, or the like which plays a role in cleaning, caring, beautifying, or the like.
The formulation of the external skin preparation is not particularly limited, and may be determined according to the use condition, such as cleansing cream, essence, emulsion, cream, lotion (e.g., toner), mask, cleansing lotion, gel, aerosol, spray, etc.
The skin external preparation containing the agalloch eaglewood hydrol can also contain other active ingredients, including one or more of a moisturizing active ingredient, a whitening active ingredient, a moisturizing active ingredient, an antioxidant active ingredient, an anti-wrinkle active ingredient, a freckle removing active ingredient, an acne removing active ingredient, a sun-screening active ingredient, an acne removing/acne active ingredient, an anti-dandruff active ingredient, an antiallergic active ingredient or a sebaceous gland-inhibiting active ingredient.
The skin external agent also contains one or more of thickener, solubilizer, cosolvent, antiseptic, surfactant, stabilizer, softener, aerosol solvent, aromatic, toner, penetration enhancer, controlled release agent, sustained release agent, humectant, emulsifier, shaping agent or pearling agent.
The cosmetic water containing the agilawood hydrosol comprises the following components in percentage by weight: 0 to 10 percent of glycerin, 0 to 6 percent of polyalcohol, 0 to 1 percent of betaine, 0 to 0.5 percent of panthenol, 0 to 0.1 percent of dipotassium glycyrrhizinate, 0 to 0.5 percent of polyethylene glycol-32, 0 to 0.2 percent of surfactant B, 0 to 0.1 percent of preservative, 0 to 0.15 percent of xanthan gum, 0 to 0.03 percent of spice, 0.001 to 100 percent of agilawood truffle and the balance of deionized water. Preferably, the sum of the weight percentages of the components is 100%. Wherein the polyalcohol is butanediol and 1, 3-propylene glycol, and the surfactant is polyglycerol-2 oleate and polyglycerol-10 oleate. The preservative is propyl hydroxybenzoate, methyl hydroxybenzoate and phenoxyethanol.
An essence containing agilawood hydrolat comprises the following components in percentage by weight: 1 to 5 percent of glycerin, 3 to 6 percent of polyalcohol, 0.5 to 1 percent of panthenol, 0 to 0.1 percent of dipotassium glycyrrhizinate, 0 to 0.1 percent of allantoin, 0.05 to 3.6 percent of surfactant, 0.25 to 0.45 percent of preservative, 0.2 to 0.4 percent of xanthan gum, 0.2 to 0.3 percent of acrylic resin Pemulen TR-2 0, 0.01 to 0.05 percent of spice, 0.001 to 95 percent of agilawood truffle and the balance of deionized water. Preferably, the sum of the weight percentages of the components is 100%. The polyalcohol is butanediol and 1, 3-propylene glycol, the surfactant is polyglycerol-2 oleate and polyglycerol-10 oleate, and the preservative B is propyl hydroxybenzoate, methyl hydroxybenzoate and phenoxyethanol.
An emulsion containing agilawood hydrosol comprises the following components in percentage by weight: 1 to 5 percent of glycerin, 2 to 8 percent of 1, 3-propylene glycol, 0.1 to 1 percent of panthenol, 0.1 to 1 percent of tocopheryl acetate, 1 to 2 percent of polydimethylsiloxane, 0.5 to 3 percent of emulsifier A165, 2 to 3 percent of oils, 1 to 3 percent of isopropyl isostearate, 0.1 to 0.5 percent of cetostearyl alcohol, 0.1 to 0.3 percent of preservative, 0.2 to 1 percent of yellow collagen, 0.01 to 0.1 percent of EDTA disodium, 0.001 to 90 percent of triethanolamine, and the balance of deionized water. Preferably, the sum of the weight percentages of the components is 100%. Triethanolamine is used to adjust the pH to 5.5-7. The oil is mineral oil and isohexadecane, and the preservative is methylparaben and propylparaben.
An emulsion containing agilawood hydrosol comprises the following components in percentage by weight: 1 to 5 percent of glycerin, 3 to 10 percent of 1, 3-propylene glycol, 0.1 to 1 percent of panthenol, 0.1 to 1 percent of tocopheryl acetate, 1 to 2 percent of polydimethylsiloxane, 1 to 3 percent of emulsifier A165, 2 to 8 percent of oil, 1 to 3 percent of isopropyl isostearate, 2 to 3 percent of cetylstearyl alcohol, 0.1 to 0.3 percent of preservative, 1 to 2 percent of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, 0.01 to 0.1 percent of EDTA disodium, 0.001 to 80 percent of triethanolamine, and the balance of deionized water. Preferably, the sum of the weight percentages of the components is 100%. Triethanolamine is used to adjust the pH to 5.5-7. The oil is mineral oil and isohexadecane, and the preservative is methylparaben and propylparaben.
In the invention, the agilawood hydrolat is condensate distilled in the agilawood essential oil extraction process, and the components are natural and pure, and the aroma is light and unique. The agalloch eaglewood hydrolat has definite and safe action mechanism, has no influence on the membrane permeability and integrity of the epidermal cells, can promote cell proliferation and increase cell ATP energy, and has good repairing effect; has good moisturizing effect, and can promote the content of epidermis hyaluronic acid, hyaluronic acid synthase 2 and aquaporin AQP 3. The skin barrier can be strengthened, the content of the pro-inflammatory factor TNF-alpha is inhibited, and the content of the inflammatory factor IL-6 is inhibited; it also improves cutaneous sensory nerve dysfunction by modulating transient receptor potential, the vanilloid subfamily member 1 (TRPV 1) receptor (also known as capsaicin receptor). In addition, the agilawood hydrolat can maintain skin stability, improve the content of epidermal cell filaggrin FLG, and the content of zonulin ZO-1 and Occludin. Meanwhile, the fluorescent lamp has an anti-photoaging effect, and can effectively reduce the ROS and superoxide contents of epidermal cells and fibroblasts caused by UV induction. Anti-aging, can improve the aging degree of fibroblasts, and promote the synthesis of type I collagen; promoting the release of natural analgesic factor beta-endorphin, and positively affecting skin problems caused by pressure. Can be used for preparing skin external preparation with antiaging, antioxidant, skin repairing, moisturizing, and skin stress reaction improving effects.
Compared with the prior art, the invention has the following advantages:
(1) The agilawood hydrolat disclosed by the invention can promote cell proliferation and expression of protein related to moisture preservation, improve the repair capability of skin, stabilize the structure and function of the skin and delay skin aging; reducing ROS and superoxide levels, inhibiting photoaging damage and antioxidant; improving cutaneous sensory nerve dysfunction, regulating TRPV1 receptor expression; inhibiting inflammatory factor release, and relieving skin inflammation; promoting the release of natural analgesic factor beta-endorphin, and positively affecting skin problems caused by pressure. Has wide application prospect as an external skin preparation, in particular to the application of cosmetics.
(2) The agilawood hydrosol extract has high activity, can generate remarkable effect under the condition of extremely low content, is natural, safe and effective, and does not irritate skin.
Drawings
FIG. 1 shows human keratinocyte/fibroblast cytotoxicity data of Aquilaria sinensis hydrolat
FIG. 2 shows ATP data of human keratinocytes/fibroblasts with agalloch eaglewood hydrol
FIG. 3 shows the cell repair data of human keratinocytes with eaglewood hydrol (scratch test)
FIG. 4 shows data on the lactate dehydrogenase content of human keratinocytes of Aquilaria sinensis hydrolat
FIG. 5 is a graph showing the effect of eaglewood hydrol on human keratinocyte Hyaluronic Acid (HA) content
FIG. 6 shows the effect of eaglewood hydrol on human keratinocyte hyaluronate synthase 2 (HAS 2) content
FIG. 7 is a graph showing the effect of Aquilaria sinensis hydrolat on human keratinocyte aquaporin (AQP 3) content
FIG. 8 is a graph showing the effect of eaglewood hydrol on human keratinocyte silk Fibroin (FLG) content
FIG. 9 is a graph showing the effect of eaglewood hydrol on human keratinocyte tight junction protein (ZO-1) content
FIG. 10 is a graph showing the effect of Aquilaria sinensis hydrolat on human keratinocyte closure protein (Occludin) content
FIG. 11 is a graph showing the effect of eaglewood hydrolat on human fibroblast (HDF) beta-galactosidase activity
FIG. 12 is a graph showing the effect of Aquilaria sinensis hydrolat on human fibroblast (HDF) type I collagen production
FIG. 13 is a graph showing the effect of eaglewood hydrol on human keratinocyte (HaCaT) calcium ion channel
FIG. 14 is a graph showing the effect of eaglewood hydrol on TRPV1 receptor protein of human keratinocyte (HaCaT) cells
FIG. 15 is a graph showing the effect of eaglewood hydrol on human keratinocyte (HaCaT) beta-endorphin content
FIG. 16 is a graph showing the effect of Aquilaria sinensis hydrolat on the content of the pro-inflammatory factor TNF- α
FIG. 17 is a graph showing the effect of eaglewood hydrolat on IL-6 content
FIG. 18 is data showing the effect of eaglewood hydrol on UV-induced ROS content in human keratinocytes
FIG. 19 is a graph showing the effect of Aquilaria sinensis hydrolat on UV-induced human keratinocyte/fibroblast superoxide molecule content
FIG. 20 is a view showing the results of safety test on a pure dew chick embryo of eaglewood
Detailed Description
The application will be further illustrated by way of example and with reference to the accompanying drawings. However, the embodiments described below are only some of the embodiments of the present application, and not all of them, so the scope of the present application should not be construed as being limited thereto.
In the specific examples of the present application, reference was made to the comparative examples, and the test environments, raw materials, etc. remained the same except for the differences that should be made among the test groups.
The test sample is provided by Hainan part of medical plant institute of China medical science. Is saturated agilawood pure dew prepared by adopting a steam distillation method. The preparation method comprises the following steps: taking agilawood powder passing through a No. 4 sieve as a raw material, taking 100g of powder and 2500mL of water, soaking in a round-bottom flask (solid-liquid ratio is 1:25) for 2 hours, connecting a volatile oil extractor and a condenser tube, continuously distilling for 6 hours at 90-100 ℃, cooling for 1 hour, collecting an agilawood saturated aqueous solution at the lower layer of oil, namely 100% saturated agilawood hydrosol, and filtering with a 0.22 mu m filter membrane for subsequent testing. The main active ingredients of the composition comprise sesquiterpenes, aromatic substances, chromones, fatty acids and other substances.
Example 1, agilawood hydrolat efficacy detection
1. Data on toxicity of eaglewood hydrol to human keratinocytes/fibroblasts
Sample preparation: cell culture medium was formulated with medium containing volume fraction 1% of green-streptomycin diabody, 10% fbs and 89% DMEM.
The testing method comprises the following steps: resuscitating HaCaT/HDF cells, and placing at 37deg.C with 5% CO 2 Culturing in environment, selecting logarithmic phase cell at 2×10 4 Density of wells/wells was seeded in 96-well plates, cell culture medium was added and incubated for 24h.
When detecting HaCaT cells, a control group and experimental groups 1-8 are arranged, culture mediums of the control group and the experimental groups 1-8 are respectively added, blank holes only containing the culture mediums are arranged, three compound holes are arranged in each group, and the culture is continued for 24 hours. The culture media of the experimental groups 1-8 respectively contain 10%, 8%, 2%, 0.5%, 0.05%, 0.01%, 0.005% and 0.001% of agilawood truffle (weight ratio), and the content of agilawood truffle in the culture media of the control group is 0%.
When detecting HDF cells, a control group and experimental groups 1-9 are arranged, culture mediums of the control group and the experimental groups 1-9 are respectively added, blank holes only containing the culture mediums are arranged, three compound holes of each group are arranged, and the culture is continued for 24 hours. The culture medium of the experimental group 1-9 contains 10%, 5%, 3%, 1%, 0.5%, 0.1%, 0.05%, 0.01% and 0.005% of agilawood truffle (weight ratio), and the content of agilawood truffle in the culture medium of the control group is 0%.
100. Mu.L of MTT solution was added to each well and incubated for 4 hours, absorbance (A) was measured at 490nm with a microplate reader, and the cell proliferation rate (RGR) was calculated as RGR= (A experimental well-A blank well)/(A control well-A blank well). Times.100%. Toxicity is evaluated according to cytotoxicity grading standards of U.S. pharmacopoeia (RGR is more than or equal to 100% and is 0 grade, more than or equal to 80% and is 1 grade, more than or equal to 50% and is 2 grade, more than or equal to 30% and is 3 grade, more than or equal to 0% and is 4 grade), cytotoxicity is considered to be free from cytotoxicity by 0-1 grade, mild toxicity is achieved by 2 grade, and moderate toxicity is achieved by 3-4 grade. The results of the testing of the toxicity data of the agilawood hydrol on human keratinocytes/fibroblasts are shown in figure 1.
The results show that the agilawood hydrosol with the content of 0.001-10% has no toxic effect on human keratinocytes/fibroblasts.
2. Effects of Aquilaria sinensis hydrosol on human keratinocyte/fibroblast cell ATP
Experimental method
Cell culture was performed as described above, and cells grown in log phase were selected to be 2X 10 4 The density of the holes is inoculated in a 96-well plate, a culture medium without serum is added overnight after the culture is carried out for 24 hours, different samples to be tested are added subsequently, a blank group without cells is arranged, a control group without cells and samples to be tested and a sample group with different concentrations are arranged, and the culture is carried out for 24 hours.
When detecting HaCaT cells, a control group and experimental groups 1-9 are arranged, culture mediums of the control group and the experimental groups 1-9 are respectively added, blank holes only containing the culture mediums are arranged, three compound holes are arranged in each group, and the culture is continued for 24 hours. The culture medium of the experimental group 1-9 contains 10%, 8%, 5%, 1%, 0.5%, 0.1%, 0.05%, 0.01% and 0.005% of agilawood truffle (weight ratio), and the content of agilawood truffle in the culture medium of the control group is 0%.
When detecting HDF cells, a control group and experimental groups 1-9 are arranged, culture mediums of the control group and the experimental groups 1-9 are respectively added, blank holes only containing the culture mediums are arranged, three compound holes of each group are arranged, and the culture is continued for 24 hours. The culture medium of the experimental group 1-9 contains 10%, 5%, 3%, 1%, 0.5%, 0.1%, 0.05%, 0.01% and 0.005% of agilawood truffle (weight ratio), and the content of agilawood truffle in the culture medium of the control group is 0%.
Preparing a standard substance and a detection solution according to the specification of an ATP detection kit, discarding the supernatant, adding 100 μl of PBS or ATP sample into each well, adding 100 μl of detection solution, shaking for 2min, incubating for 10min at room temperature in a dark place, and reading by a fluorescent microplate detector.
The experimental results are shown in fig. 2, and the results show that 10%, 8%, 5%, 1%, 0.5%, 0.1%, 0.05%, 0.01% of agilawood hydrosol can promote the ATP of human keratinocytes to be energized, while 10%, 5%, 3% of agilawood hydrosol can promote the ATP of fibroblasts to be energized, and the energy is provided for the growth and the development of the cells and the physiological effects by the remarkable difference (P values are respectively <0.001, 0.001 and 0.05).
The above results show that the content of the agilawood truffle is more than 0.01wt% and can promote the ATP of human keratinocytes to be energized, and the content of the agilawood truffle is more than 3wt% and can promote the ATP of fibroblasts to be energized.
3. Reparation of human keratinocyte by eaglewood hydrol
The experimental method comprises the following steps: human keratinocytes (HACAT) were inoculated into 6-well plates at 1000000 per well, after 24h of incubation, a straight line scratch was drawn vertically at the center of the well with a gun head, floating cells were washed off with PBS, the incubation with test samples was performed, a blank control group and a sample group were set, after 24h, cell culture solution was discarded, cells were fixed with tissue fixative, stained with Giemsa stain for 15min, washed clean with running water and air dried, and photographed with a microscope.
The experimental results are shown in FIG. 3. Fig. 3 shows the data of human keratinocyte cell repair of agalloch eaglewood hydrol (scratch test).
The results show that 10% and 0.5% of agilawood hydrol have a certain repairing effect on scratches of keratinocytes, and promote cell migration.
4. Effects of Aquilaria sinensis Probeol on human keratinocyte lactate dehydrogenase
The experimental method comprises the following steps: human keratinocyte (HACAT) is inoculated into a 96-well plate at 20000/well, after culturing for 24 hours, a sample to be detected is added for culturing, a blank control group and a sample group are arranged, cell lysate and Triton X-100 are taken as references, after 24 hours, supernatant fluid is taken and centrifuged, then the mixture is added into a new 96-well plate, LDH working solution is added, the mixture is uniformly mixed, incubation is carried out at room temperature for 30 minutes in a dark place, and the light absorption value is measured at 490 nm.
The experimental results are shown in FIG. 4, and FIG. 4 shows the lactic dehydrogenase content of human keratinocytes treated with eaglewood hydrosol. The results show that 10% -0.5% of agilawood hydrosol extracellular lactate dehydrogenase has no significant difference from the control group, and the results show that the content of agilawood hydrosol extracellular lactate dehydrogenase has no influence on the membrane permeability and integrity of keratinocytes.
5. Moisture-keeping effect of agilawood hydrosol
5.1 effects of Aquilaria sinensis Probex on Hyaluronic Acid (HA) content of human keratinocytes
The experimental method comprises the following steps: human keratinocytes (HACAT) were inoculated in 24 well plates containing climbing plates at 100000/well, cultured for 24 hours, added with samples to be tested, set up a blank control group and a sample group, after 24 hours, discarded the cell culture fluid, fixed cells with tissue fixative, permeabilized cells with triton x-100, blocked with 5% bsa at the redundant sites, combined with hyaluronic acid primary antibody, incubated overnight at 4 ℃ and combined with secondary antibody for 1 hour, nuclei were stained with DAPI for 5min, and photographed with a microscope.
The experimental results are shown in fig. 5, and the results show that 8% -12% of agilawood hydrolat can promote keratinocytes to synthesize hyaluronic acid by using green immunofluorescence to calibrate hyaluronic acid.
5.2 Effect of Aquilaria sinensis hydrosol on human keratinocyte hyaluronate synthase 2 (HAS 2) content
The experimental method comprises the following steps: human keratinocytes (HACAT) were inoculated in 24 well plates containing slide plates at 100000/well, cultured for 24 hours, added with samples to be tested, set up a blank control group and a sample group, after 24 hours, discarded the cell culture fluid, fixed cells with tissue fixative, permeabilized cells with triton x-100, blocked with 5% bsa at the redundant sites, combined with primary hyaluronidase 2 antibody, incubated overnight at 4 ℃ and combined with secondary antibody for 1 hour, nuclei were stained with DAPI for 5min, and photographed with a microscope.
The experimental results are shown in fig. 6, and the results show that the green immunofluorescence is used for calibrating the hyaluronic acid synthase 2, and the results show that 8% -12% of agilawood hydrolat can promote the increase of the hyaluronic acid synthase 2 of keratinocytes.
5.3 effects of Aquilaria sinensis Probex on human keratinocyte aquaporin (AQP 3) content
The experimental method comprises the following steps: human keratinocytes (HACAT) were inoculated into 24-well plates containing climbing plates at 100000/well, cultured for 24 hours, then added with samples to be tested, a blank control group and a sample group were set, cell culture fluid was discarded after 24 hours, cells were fixed with tissue fixative, cells were permeabilized with Triton X-100, redundant sites were blocked with 5% BSA, aquaporin primary antibody was bound, incubated overnight at 4℃and secondary antibody was bound for 1 hour, nuclei were stained with DAPI for 5 minutes, and microscopic photographs were taken.
The experimental results are shown in fig. 7, and the green immunofluorescence is used for calibrating aquaporins, and 8% -12% of agilawood hydrosol can promote the increase of the keratinocyte aquaporins.
6. Agilawood hydrolat tough skin barrier
6.1, data of the influence of Aquilaria sinensis hydrolat on the content of human keratinocyte Filaggrin (FLG)
The experimental method comprises the following steps: human keratinocytes (HACAT) were inoculated into 24-well plates containing climbing plates at 100000/well, cultured for 24 hours, then added with samples to be tested, a blank control group and a sample group were set, cell culture fluid was discarded after 24 hours, cells were fixed with tissue fixative, then TritonX-100 permeabilized cells were used, redundant sites were blocked with 5% BSA, silk fibroin primary antibody was bound, incubated overnight at 4℃and secondary antibody was bound for 1 hour, nuclei were stained with DAPI for 5 minutes, and microscopic photographs were taken.
As shown in the experimental result in FIG. 8, the increase of keratinocyte silk fibroin can be promoted by using green immunofluorescence to calibrate silk fibroin and 8% -12% of agilawood hydrosol.
6.2 data of the effect of Aquilaria sinensis hydrolat on human keratinocyte tight junction protein (ZO-1) content
The experimental method comprises the following steps: human keratinocytes (HACAT) were inoculated into 24-well plates containing slide plates at 100000/well, cultured for 24 hours, then added with samples to be tested, a blank control group and a sample group were set, cell culture fluid was discarded after 24 hours, cells were fixed with tissue fixative, cells were permeabilized with Triton X-100, redundant sites were blocked with 5% BSA, binding to zonin ZO-1 primary antibody, incubated overnight at 4℃and binding to secondary antibody for 1 hour, nuclei were stained with DAPI for 5 minutes, and photographed with a microscope.
The experimental results are shown in fig. 9, and the result shows that 8% -12% of agilawood hydrolat can increase the content of the keratinocyte tight junction protein ZO-1 and strengthen the tight junction among cells by using green immunofluorescence to calibrate the tight junction protein ZO-1.
6.3 data of the effect of Aquilaria sinensis hydrolat on human keratinocyte closure protein (Occlutin) content
The experimental method comprises the following steps: human keratinocytes (HACAT) were inoculated in 24 well plates containing slide plates at 100000/well, cultured for 24h, added with samples to be tested, set up blank control and sample groups, after 24h cell culture fluid was discarded, cells were permeabilized with triton x-100 after fixing cells with tissue fixative, excess sites were blocked with 5% bsa, combined with the Occludin primary antibody, incubated overnight at 4 ℃, combined with the secondary antibody for 1h, nuclei were stained with DAPI for 5min, and photographed with a microscope.
The experimental results are shown in fig. 10, and the content of the keratinocyte occluding protein can be improved by using green immunofluorescence to calibrate transparent occluding protein Occludin and 12% -8% of agilawood hydrosol.
7. Anti-aging effect of agilawood hydrolat
7.1 Effect of Aquilaria sinensis hydrosol on human fibroblast (HDF) beta-galactosidase Activity
The experimental method comprises the following steps: human fibroblast (HDF) is inoculated into a 6-hole plate at 100000/hole, after culturing for 24h, a sample to be tested is added for culturing, a blank control group, a model group and a sample group are arranged, after 24h, cell culture solution is discarded, after washing cells for 2 times by PBS, the supernatant is changed into PBS, three layers of tinfoil paper is used for covering the hole of the blank group, and the cell culture solution is used for covering the hole of the blank group by 12.5J/cm 2 The cells are irradiated by UVA at a dosage, after the irradiation is finished, the supernatant PBS is sucked, the cells are continuously cultured for 24 hours by changing into a serum-free culture medium prepared by medicine, then the cells are fixed by a beta-galactosidase staining fixing solution for 15 minutes, then a staining working solution is added, the cells are incubated overnight at 37 ℃, and the next day is photographed and observed.
The experimental results are shown in FIG. 11. The results show that 10% and 3% of agilawood hydrol have different degrees of inhibition on beta-galactosidase produced by fibroblasts compared with a UVA group, and help the cells resist cell aging caused by UV.
7.2 Effect of Aquilaria sinensis hydrosol on human fibroblast (HDF) type I collagen production
The experimental method comprises the following steps: human fibroblast (HDF) is inoculated into a 24-hole plate containing a climbing plate at 100000/hole, a sample to be detected is added for culture after 24 hours of culture, a blank control group, a model building group and a sample group are arranged, a cell culture solution is discarded after 24 hours, after the cells are washed for 2 times by PBS, the supernatant is changed into PBS, three layers of tinfoil paper is used for covering the holes of the blank group, and the holes are covered by 12.5J/cm 2 The cells are irradiated by UVA at a dosage, after the irradiation is finished, the supernatant PBS is sucked, the cells are continuously cultured for 24 hours by changing into a serum-free culture medium prepared by medicaments, collagen is enriched, 0.1mg/mL VC+7 mu g/mL VE is used as a positive control, after 24 hours, the cells are fixed by tissue fixing solution, the cells are penetrated by Triton X-100, the redundant sites are blocked by 5% BSA, the primary antibodies are combined with the type I collagen, the primary antibodies are incubated overnight at 4 ℃, the secondary antibodies are combined for 1 hour, the nuclei are stained with DAPI for 5 minutes, and the microscopic photographing and observation are carried out.
The experimental results are shown in fig. 12, and the results show that 10%, 3% and 1% of agilawood hydrolat have different degrees of promotion effects on the generation of fibroblast type I collagen compared with the UVA group.
8. Agilawood hydrolat has pain relieving effect
8.1 effects of Aquilaria sinensis hydrolat on human keratinocyte (HaCaT) calcium ion channel
The experimental method comprises the following steps: human keratinocytes (HACAT) were inoculated into 24-well plates containing climbing slices at 100000/well, cultured for 24 hours, then added with samples to be tested, a blank control group, a model group and a sample group were set, 40nM capsaicin was added to the model group, the sample group was co-cultured with the sample using 40nM capsaicin, after 24 hours, fluo-4 fluorescent working solution was added, incubated at 37℃for 30 minutes, washed with PBS, then incubated with PBS at 37℃for 15 minutes, the climbing slices were taken out, and photographed with a fluorescent microscope.
As shown in the experimental results in FIG. 13, compared with the capsaicin group, 10% and 3% of the agilawood hydrolat have a certain effect of inhibiting the opening of calcium ion channels, and provide a barrier for resisting external stimulus for cell membranes.
8.2 effects of Aquilaria sinensis Probex on human keratinocyte (HaCaT) cell TRPV1 receptor protein
The experimental method comprises the following steps: human keratinocytes (HACAT) were inoculated in 24-well plates containing climbing plates at 100000/well, cultured for 24 hours, then added with samples to be tested, a blank control group, a model group and a sample group were set, 40nM capsaicin was added to the model group, the sample group was co-cultured with the sample using 40nM capsaicin, cell culture solution was discarded after 24 hours, cells were fixed with tissue fixative, cells were permeabilized using Triton X-100, redundant sites were blocked with 5% BSA, TRPV1 receptor protein primary antibody was bound, incubated overnight at 4℃and secondary antibody was bound for 1 hour, nuclei were stained with DAPI for 5 minutes, and microscopic photographs were taken for observation.
As shown in fig. 14, 10% and 3% of the agilawood hydrolat can reduce the TRPV1 receptor protein content and relieve the stimulation of capsaicin production compared with the capsaicin group.
In conclusion, the agilawood hydrolat has the function of relieving skin pain, and can improve the sensory nerve dysfunction of the skin and improve the skin stress response.
9. Agilawood hydrolat promoting beta-endorphin release
The effect of eaglewood hydrol on human keratinocyte (HaCaT) beta-endorphin content was studied as follows:
the experimental method comprises the following steps: human keratinocytes (HACAT) were inoculated in 24-well plates at 100000/well, cultured for 24 hours, then added with samples to be tested, a blank group, a model group and a sample group were set, 40nM capsaicin was added to the model group, IL-1 beta was used as a reference, and after 24 hours, cell supernatants were taken and the beta-endorphin content was detected by an Elisa kit.
The experimental results are shown in fig. 15, and the results show that 10% and 3% of agilawood hydrolat can promote cells to release beta-endorphin, and have significant differences (P <0.001 and P < 0.01).
The results prove that the agilawood hydrolat can promote the release of beta-endorphin, thereby relieving pain and improving skin stress response.
10. Effects of Aquilaria sinensis Proinflammatory factors TNF-alpha and IL-6
The experimental method comprises the following steps: the effect of the test sample on the release of the pro-inflammatory factor TNF-alpha/IL-6 was determined by enzyme-linked immunosorbent assay (ELISA). The effect of the sample to be tested on the release of inflammatory factor TNF-alpha/IL-6 was measured by ELISA, and the experimental Human TNF-alpha/IL-6 ELISA kit was purchased from Hangzhou Union Co., ltd. The THP-1 cells in the logarithmic growth phase were used with the cells containingRPMI 1640 medium of 100nmol/L phorbol ester 12-tetradecanoate 13-acetate (PMA) was adjusted to a cell density of 6X 10 5 Inoculating each of the above-mentioned materials into 24-well plate at 37deg.C with 5% CO 2 Is cultured in a constant temperature incubator for 72 hours. After the cultivation is finished, the original liquid is sucked, PBS is washed for 3 times, a sample to be detected, a positive control group and a negative control group are added for continuous cultivation for 24 hours, wherein the sample to be detected is co-cultivated with 1 mug/ml Lipopolysaccharide (LPS) to be used as a sample group, the positive control group only contains 1 mug/ml LPS, and the negative control group only contains pure RPMI 1640 culture medium. After the incubation, the supernatant from each well was collected and assayed for TNF- α/IL-6 content by reference to ELISA kit instructions. TNF- α/IL-6 levels were determined by standard curves obtained from each experimental standard. The inhibition of pro-inflammatory factors by the samples was calculated by the following formula.
Inhibition (%) = (1-T/C) ×100%
Wherein, the average value of the content of the pro-inflammatory factors of the T-test object and the average value of the content of the pro-inflammatory factors of the C-negative control group.
The effect of the compositions at different ratios on TNF- α release is shown in FIG. 16. The determination of the amount of TNF-alpha released by the cells treated by the agilawood hydrolat with different ratios shows that 3% -10% of agilawood hydrolat can reduce the release of TNF-alpha to a certain extent. The inhibition of TNF- α release was calculated for each sample and the results are shown in Table 1.
TABLE 1 inhibition of the release of the proinflammatory factor TNF-alpha by eaglewood puredew
Final test concentration | Inhibition rate | p |
10% | 49.05% | <0.01 |
5% | 48.55% | <0.01 |
3% | 49.33% | <0.01 |
1% | 0.95% | - |
0.5% | 2.54% | - |
The effect of the compositions at different ratios on the amount of IL-6 released is shown in FIG. 17. The measurement of the amount of IL-6 released by the cells treated by the agilawood hydrolat with different ratios shows that 0.5% -10% of agilawood hydrolat can reduce the release of IL-6 to a certain extent. The inhibition rate of IL-6 release amount by each sample was calculated, and the results are shown in Table 2.
TABLE 2 inhibition of inflammatory factor IL-6 Release by eaglewood hydrol
Final test concentration | Inhibition rate | p |
10% | 46.09% | <0.001 |
5% | 45.21% | <0.001 |
3% | 47.19% | <0.001 |
1% | 27.84% | <0.001 |
0.5% | 34.00% | <0.001 |
In conclusion, the agilawood hydrolat can inhibit inflammatory factors, so that the stress response of the skin is improved.
11. Photodamage experiments
11.1 effects of eaglewood hydrol on UV-induced ROS content of human keratinocytes.
Reactive Oxygen Species (ROS) are detected by a fluorescent probe DCFH-DA to compare the cell efficacy of the agalloch eaglewood hydrol in resisting UV stimulation. The method comprises the following steps:
cell culture: normal human keratinocytes HACATHACAT were grown in T175 flasks using DMEM medium +10% serum of holly leaf +1% penicillin/streptomycin/amphotericin. For the subsequent quantitative experiment of the enzyme-labeled instrument, the method uses 2X10 4 Density of individual/well in 96 well plate and 2X10 6 The density of individual/wells was seeded in 6-well plates. After 24 hours, preparing sample solutions with different concentrations by using a serum-free culture medium, pre-treating the cells for 2 hours,then removing the original culture solution, adding a fluorescent probe DCFH-DA with the final concentration of 1uM/mL, incubating with the cells for 30min, and then carrying out subsequent active oxygen induction and detection experiments. The cells were kept cultured at 37℃with 5% CO 2 Is provided.
UV-induced ROS: after the probe incubation is completed, the cells are irradiated by UV and absorbance is measured at 485/535nm by a fluorescent microplate detector.
Results as shown in fig. 18, all experimental groups had the ability to significantly reduce ROS levels compared to the stimulated group in the UV-induced photoaging damage model.
11.1.2 inhibition of UV-induced superoxide by Aquilaria sinensis hydrolat
Cell culture was performed as described above, and 1X10 of HDF cells in logarithmic growth phase were selected 5 Density of holes is planted in a 24-hole plate containing a climbing sheet, a sample to be detected is added after the 24-hole plate is cultured for 24 hours, and a blank group, a module and a sample group are arranged. UVA irradiation is carried out on the model building module and the sample group at the speed of 10J/cm < 2 >, after 3h of irradiation, a fluorescent probe MitoSOX with the final concentration of 1uM/mL is added to incubate with cells for 30min, and nuclear dyeing is carried out for 5min by using DAPI, and microscopic photographing and observation are carried out.
As shown in fig. 19, compared with the UVA model, 10% of agilawood hydrolat can reduce the level of superoxide in mitochondria of fibroblasts, and has the capacity of targeting mitochondrial antioxidation.
In view of the above-mentioned, it is desirable,
12. safety test result of agilawood hydrolat
The chick embryo allantoic vessel test is an organotypic animal substitution test for evaluating ocular irritation of a subject. The method is to act the test object on the allantoic membrane of the chick embryo to observe the influence of the test object on the blood vessels on the membrane, so as to judge the eye irritation of the test object. For mammals, the observed effect of the allantoic membrane can be used to mimic the conjunctival stimulating response of the subject in an in vivo experiment. At the same time, the model can simulate the stimulation of the eye conjunctiva tissue by the substance.
The experimental method comprises the following steps: by utilizing the characteristic that the chorioallantoic vascular system in the middle period of fertilized chick embryo of 14 days of incubation is obvious in integrity and permeable, a certain amount of the test object is directly contacted with the chick embryo chorioallantoic membrane, and the chorioallantoic vascular injury condition is observed after a period of action, so that the potential stimulation of the test object is evaluated. The vascular effect evaluation was performed according to the observation of vascular injury conditions by the following criteria: 40 μl of raw material stock solution of Chinese eaglewood hydrosol is taken as a test sample, and 6 samples are taken in parallel.
The chick embryos are placed in an incubator for 30 minutes. After 30 minutes incubation, the preservative film was removed, and the changes in the CAM vessels were observed and compared under supplemental light, as shown in fig. 20, to evaluate the in-loop vascular damage.
The experimental results show that: the raw material stock solution of the agilawood hydrosol has no influence on the vascular injury of chick embryos, passes through the safety, and has no stimulation to eyes.
Example 2
(1) Toning lotion containing agilawood hydrosol
The toner is prepared according to the following components and the following dosage by a preparation method of the conventional toner in the field.
5 parts of glycerin, 3 parts of polyalcohol A, 1 part of betaine, 0.5 part of panthenol, 0.05 part of dipotassium glycyrrhizinate, 0.5 part of polyethylene glycol-32, 0.1 part of surfactant B, 0.1 part of preservative C, 0.1 part of xanthan gum and 0.03 part of spice, wherein the raw materials are complemented to 100 parts by agalloch eaglewood hydrosol; or adding 0.001-94 parts of agilawood hydrosol, and supplementing to 100 parts by deionized water.
The polyalcohol A is butanediol and 1, 3-propanediol. The surfactant B is polyglycerol-2 oleate and polyglycerol-10 oleate. The preservative B is propyl hydroxybenzoate, methyl hydroxybenzoate and phenoxyethanol. The acrylic resin Pemulen TR-2 is an acrylic acid (ester) based/C10-30 alkanol acrylate cross-linked polymer. Xanthan gum is an extracellular microbial polysaccharide produced by fermentation of Xanthomonas.
The percentages refer to the weight percentages of the components in the toning lotion: 0.001-10% of glycerin, 0-6% of polyalcohol A, 1% of betaine, 0.5% of panthenol, 0-0.1% of dipotassium glycyrrhizinate, 0-0.5% of polyethylene glycol-32, 0-0.2% of surfactant B, 0.4-0.1% of preservative C, 0-0.15% of xanthan gum, 0-0.03% of spice and the balance of agilawood extract, wherein the sum of the weight percentages of the components is 100%.
Wherein the weight percentage of the agilawood hydrosol is 0.001-100%.
(2) Essence containing agilawood hydrosol
The essence is prepared according to the following components and parts by weight according to a preparation method of the conventional essence in the field.
5 parts of glycerin, 4 parts of polyalcohol B, 1 part of panthenol, 0.1 part of dipotassium glycyrrhizinate, 0.1 part of allantoin, 1 part of surfactant B, 0.3 part of preservative B, 0.3 part of xanthan gum, 0.3 part of acrylic resin Pemulen TR-2 and 0.03 part of spice, wherein the raw materials are supplemented to 100 parts by agalloch eaglewood hydrosol; or adding at least 0.001 part of agilawood hydrosol, and supplementing to 100 parts by deionized water.
The polyalcohol B is butanediol and 1, 3-propanediol. The surfactant B is polyglycerol-2 oleate and polyglycerol-10 oleate. The preservative B is propyl hydroxybenzoate, methyl hydroxybenzoate and phenoxyethanol. The acrylic resin Pemulen TR-2 is an acrylic acid (ester) based/C10-30 alkanol acrylate cross-linked polymer. Xanthan gum is an extracellular microbial polysaccharide produced by fermentation of Xanthomonas. The external preparation for skin in this example was prepared.
(3) Emulsion containing agilawood hydrosol
The emulsion is prepared according to the following components and weight parts by the preparation method of the emulsion conventional in the field.
5 parts of glycerin, 5 parts of 1, 3-propylene glycol, 1 part of panthenol, 0.5 part of tocopheryl acetate, 2 parts of polydimethylsiloxane, 165 parts of emulsifier A, 2-3 parts of oil C, 3 parts of isopropyl isostearate, 0.5 part of cetostearyl alcohol, 0.3 part of preservative C, 0.5 part of yellow collagen, 0.1 part of EDTA disodium, 1 part of triethanolamine and 100 parts of the raw materials are complemented by agilawood hydrosol; or adding at least 0.001 part of agilawood hydrosol, and supplementing to 100 parts by deionized water. The external preparation for skin in this example was prepared.
Triethanolamine is used to adjust the pH of the emulsion to 5.5-7. The oil C is mineral oil and isohexadecane. Preservative C is methylparaben and propylparaben. Emulsifier A165 is emulsifier A165 containing glycerol stearate and PEG-100 stearate. Xanthan gum is an extracellular microbial polysaccharide produced by fermentation of Xanthomonas.
(4) Cream containing agilawood hydrosol
The cream is prepared according to the following components and weight parts by the preparation method of the cream conventional in the field.
5 parts of glycerin, 5 parts of 1, 3-propylene glycol, 1 part of panthenol, 0.5 part of tocopheryl acetate, 2 parts of polydimethylsiloxane, 165 parts of emulsifier A, 5 parts of oil D, 3 parts of isopropyl isostearate, 2 parts of cetostearyl alcohol, 0.3 part of preservative D, 2 parts of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, 0.1 part of EDTA disodium, 1 part of triethanolamine and the balance of agilawood hydrosol to 100 parts; or adding at least 0.001 part of agilawood hydrosol, and supplementing to 100 parts by deionized water.
Triethanolamine is used to adjust the pH of the cream to 5.5-7. Oil D is mineral oil and isohexadecane. Preservative D is methylparaben and propylparaben.
Claims (9)
1. The application of the agilawood hydrolat in the aspect of preparing skin care products is characterized in that the skin care products have at least one of the following functions: anti-aging, antioxidant, moisturizing, improving skin stress, inhibiting photoaging damage or repairing skin.
2. The application of the agilawood hydrolat in the aspect of preparing skin care products is characterized in that the skin care products have at least one of the following functions: promoting proliferation of keratinocyte or fibroblast, stabilizing skin structure and function, strengthening skin barrier, improving skin sensory nerve dysfunction, relieving skin pain, relieving skin inflammation, and improving oxidation resistance of mitochondria.
3. The application of the agilawood hydrolat in the aspect of preparing skin care products is characterized in that the skin care products have at least one of the following functions: promoting ATP energization of keratinocytes and fibroblasts, promoting keratinocyte repair and migration, promoting synthesis of hyaluronic acid by keratinocytes, increasing content of hyaluronic acid synthase 2 in keratinocytes, and promoting synthesis of aquaporin by keratinocytes.
4. The application of the agilawood hydrolat in the aspect of preparing skin care products is characterized in that the skin care products have at least one of the following functions: the content of the keratinocyte tight junction protein ZO-1 is improved, the tight junction among cells is enhanced, and the content of the keratinocyte closure protein is improved.
5. The application of the agilawood hydrolat in the aspect of preparing skin care products is characterized in that the skin care products have at least one of the following functions: inhibit galactosidase activity or promote the production of type I collagen by fibroblasts.
6. The application of the agilawood hydrolat in the aspect of preparing skin care products is characterized in that the skin care products have at least one of the following functions: inhibiting UV-induced ROS, inhibiting UV-induced superoxide or reducing superoxide levels within the mitochondria of fibroblasts.
7. The application of the agilawood hydrolat in the aspect of preparing skin care products is characterized in that the skin care products have at least one of the following functions: promote the secretion of beta-endorphin by fibroblasts, inhibit the production of inflammatory factors or inhibit the production of TRPV1 receptor proteins.
8. The use according to any one of claims 1 to 7, wherein the content of the agalloch eaglewood hydrol in the skin care product is 0.001wt% to 100wt%.
9. A skin external preparation comprising agalloch eaglewood hydrolat and having the functions of any one of claims 1 to 7.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210264828.2A CN116785209A (en) | 2022-03-17 | 2022-03-17 | Application of agilawood hydrolat and skin external preparation containing agilawood hydrolat |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210264828.2A CN116785209A (en) | 2022-03-17 | 2022-03-17 | Application of agilawood hydrolat and skin external preparation containing agilawood hydrolat |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116785209A true CN116785209A (en) | 2023-09-22 |
Family
ID=88033204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210264828.2A Pending CN116785209A (en) | 2022-03-17 | 2022-03-17 | Application of agilawood hydrolat and skin external preparation containing agilawood hydrolat |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116785209A (en) |
-
2022
- 2022-03-17 CN CN202210264828.2A patent/CN116785209A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114099409B (en) | Relief repair composition and application thereof | |
CN115317429A (en) | Composition containing recombinant collagen and having repairing and relieving effects, eye cream containing composition, preparation method and application | |
CN107929166A (en) | A kind of pro-skin massage oil and preparation method thereof | |
CN112451439A (en) | Skin conditioning composition and skin care product containing cannabidiol | |
KR20210004672A (en) | External composition including high pressure homogenizing extract of plant and manufacturing method for the same | |
KR20200053815A (en) | A cosmetic composition for improving skin containing a peptide | |
CN110392576A (en) | Cosmetic composition comprising a combination of phellinus igniarius oil and 4-tert-butylcyclohexanol for the treatment of rosacea | |
KR101587447B1 (en) | Cosmetic composition with BL-S extract by the supercritical extraction with the effect of skin sebum control, skin barrier intention, skin moisture control and skin protection | |
KR20180083782A (en) | Cosmetic composition comprising withania somnifera, morus australis and pure tea extracts | |
CN116492385A (en) | Compound essential oil for repairing skin and pharmaceutical composition containing compound essential oil | |
CN115089645B (en) | Composition and skin care product for inhibiting TRPV1 pathway and reducing skin irritation | |
KR20150097336A (en) | Cosmetic Composition have Atopic cure and prevention efficacy | |
CN115429725B (en) | Cosmetic composition for antioxidation, anti-inflammatory and skin tranquilization | |
CN116785209A (en) | Application of agilawood hydrolat and skin external preparation containing agilawood hydrolat | |
CN113940909B (en) | Composition for regulating circadian rhythm and application thereof | |
CN110200870A (en) | A kind of reparation moisture retention water containing solanum lyratum and Flos Hibisci extract | |
KR100369578B1 (en) | Cosmetics containing natural herb extract having wrinkle-curing activity | |
KR20030015654A (en) | Skin external compositions containing raspberry leaf or fruit extract for reducing irritation and inflammation in skin | |
KR20100067700A (en) | Cosmetic compositions for skin care containing extract of tussilago farfara linne flower | |
KR20090085844A (en) | Cosmetic composition containing natural medicinal plant extract for alleviating skin inflammation | |
CN114344289A (en) | Composition with anti-aging activity and preparation and application thereof | |
KR20220070122A (en) | A composition for skin anti-pollution containing a daughter-in-law navel extract | |
KR20090042073A (en) | Compositions of the specific herb extracted complex which has the function of alleviating the irritation and those of cosmetics for allergic skin containing it | |
CN111821331A (en) | External gel for repelling mosquitoes, relieving itching and diminishing swelling and preparation method thereof | |
KR102335679B1 (en) | Composition for enhancing skin cell regeneration or wound healing containing absolute of Salix koreensis ANDERSS. flower |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 201403 Shanghai City, Fengxian District Lifenglu No. 12 Applicant after: Shanghai Natural Hall Group Co.,Ltd. Address before: 201403 Shanghai City, Fengxian District Lifenglu No. 12 Applicant before: JALA Group Co. |